Summary of Inventions
A major limitation of cancer immunotherapy is that natural tumor antigens elicit weak T cell responses, partly because the high-affinity T cells are rendered tolerant to these antigens. Scientists at Memorial Sloan-Kettering Cancer Center have developed potent DNA vaccines against cancer and infectious diseases.
- SK 758 refers to a method of engineering the nucleic acid sequence or the peptide sequence of an antigen to improve the interaction of the antigenic peptide with the major histocompatibility complex (MHC) on APCs for better presentation to the T cells, resulting in an improved cellular immune response.
- SK 1083 is computer software application to help design rapidly and rationally antigenic epitopes modified to improve the cellular immune response.
- SK 1094 refers to a method and composition for a therapeutic vaccine comprised of DNAs coding for a combination of vascular and differentiation antigens that are more effective when both antigens are used instead of being administered alone.
Patent Information
Patent protection available; the software is protected by copyright.
Contact Information
Julia Calonge, PhD
E-mail: calongej@mskcc.org
Viviane Martin, PhD
E-mail: martinv@mskcc.org
Tel: 212-639-6181; Fax: 212-717-3439
